



A chemoselective synthesis and biological evaluation of novel benzo[*g*]thiazolo[3,2-*a*]quinolone derivatives


Mohammad Bayat¹ · Fatemeh Safari² · Shima Nasri¹ · Fahimeh Sadat Hosseini¹

Received: 25 September 2018 / Accepted: 14 November 2018 / Published online: 26 February 2019
© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Abstract

A novel approach for chemoselective synthesis of functionalized benzo[*g*]thiazolo[3,2-*a*]quinolones from dithioacetals, cysteamine hydrochloride, 2-hydroxy-1,4-naphthoquinone, and aromatic aldehydes in ethanol is described. All products were tested *in vitro* for their cytotoxic effects on lung, breast, and prostate cancer cells.

Graphical abstract



Keywords Nitroketene dithioacetals · Thiazolo[3,2-*a*]pyridines · Cytotoxic activity · Cancer cells

Introduction

Over the past decade, sulfur–nitrogen heterocyclic compounds have attracted much attention of an increasing number of pharmaceutical and agrochemical researchers, due to their versatile biological activity, unusual physical properties and also existence of these groups in a broad range of pharmaceuticals and natural products. Their unique physical

properties in the molecular structure, especially from magnetism and conductivity aspects, are due to the availability of unshared pairs of electrons and the difference in electronegativity between heteroatoms and carbon [1, 2].

Among such sulfur–nitrogen containing heterocycles, thiazolo[3,2-*a*]pyridines are an important class of compounds with two different fused heterocycles, which are found in a broad range of compounds possessing a variety of biological activities. These compounds act as potent CDK2-cyclin A inhibitor [3], potential uterus stimulant [4], beta-amyloid production inhibitor [5], coronary dilator, antibacterial and antifungal agent [6], and scavenger of free radicals because of possessing electron acceptors and donors [7]. Also, these derivatives play an important role in the drug development for chemotherapy of various cancers, such as leukemia, lung cancer, and melanoma [8, 9]. Some important thiazolopyridine scaffolds from the biological point of view are presented in Fig. 1 [10–12].

Furthermore, to increase the therapeutic properties of thiazolo[3,2-*a*]pyridines, we synthetically attached the 1,4-naphthoquinone ring, with various biologic activities,

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00706-018-2337-1>) contains supplementary material, which is available to authorized users.

✉ Mohammad Bayat
bayat_mo@yahoo.com; m.bayat@sci.ikiu.ac.ir

✉ Fatemeh Safari
fsafari@guilan.ac.ir

¹ Department of Chemistry, Imam Khomeini International University, Qazvin, Iran

² Department of Biology, Faculty of Science, University of Guilan, Rasht, Iran




Fig. 1 Related thiazolopyridines as new medical treatment reagents

such as antimalarial, antibacterial, cytotoxic, antifungal, antiviral, and anti-inflammatory, and unique properties, such as redox and acid–base properties to these scaffolds [13, 14].

Cancer is one of the leading causes of death worldwide and the exploration of new potential approaches for cancer treatment including the design of novel anti-cancer drugs is one of the important strategies [15]. Because of the biological importance and anti-cancer activities of thiazolo[3,2-*a*]pyridines, numerous procedures have been developed for the synthesis of these components [5, 7, 16–19]. Although previous studies have shown the synthesis of compounds with similar structures, developing new methods for the synthesis of sulfur-containing pharmaceutical compounds seems to be essential. Herein, we describe our results in the synthesis of several derivatives of thiazolo[3,2-*a*]pyridines and the evaluation of their *in vitro* cytotoxic activity against tumor cells, including A549 cells, MCF-7 cells, and PC3 cells using MTT assay. Finally, we showed cell death by evaluation of nucleus of cells by using DAPI staining.

Results and discussion


Chemistry

In this regard, and in continuation of our previous works based on the discovery of new heterocycles with potentially


biological activities [20–23], herein we would like to report a novel efficient one-pot strategy for the synthesis of 4-nitro-5-phenyl-1,2-dihydro-5*H*-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione via condensation of β -nitrothiazolidine as an enamine analog, 2-hydroxy-1,4-naphthoquinone, and aromatic aldehydes under mild reaction condition in ethanol (Scheme 1). In this paper, ethanol was used as an inexpensive and environmentally friendly solvent, which is miscible with water [24, 25]. β -Nitrothiazolidine derived from the addition of cysteamine hydrochloride to 1,1-bis(methylthio)-2-nitroethene was also used. Its electron donation of nitrogen and sulfur atoms increased the electron density of the carbon at the β -position to nitrogen, which acted as the nucleophile [18, 26, 27].

The reaction mechanism, on the basis of the results obtained, is designated in Scheme 2. To form product **5**, it is possible that initially the formation of β -nitrothiazolidine (**6**) occurs through the addition of cysteamine hydrochloride (**1**) to 1,1-bis(methylthio)-2-nitroethene (**2**) in the presence of an equivalent amount of triethylamine base for the release of cysteamine salts. Then Michael acceptor **7** occurs through Knoevenagel condensation between aromatic aldehydes **3** and 2-hydroxy-1,4-naphthoquinone (**4**) that is followed by loss of water molecules. β -nitrothiazolidine then adds to the Knoevenagel adduct **7** in a Michael addition to give open chain intermediate **8**, which undergoes successive imine–enamine tautomerization, followed by N-cyclization

Scheme 1



Scheme 2



via attack of the secondary amino group to the more reactive carbonyl group of 2-hydroxy-1,4-naphthoquinone to give product **5**.

In this method, chromatography and recrystallization did not need purification; the mixture was filtered and the precipitate washed with EtOH (96%) to afford the pure product **5**. As shown in Table 1, several functionalities present in the aryl moiety such as halogen, hydroxyl, and nitro groups in *ortho* or *para* position were tolerated and worked well with different efficiencies.

The second step was completed after 1–8 h in EtOH and afforded the corresponding heterocyclic systems **5a–5l**, in good to excellent yields (68–95%). The structures of the separated crude products were clearly deduced from their elemental analyses, IR, ^1H , ^{13}C NMR, and mass spectra. The mass spectrum of **5a** displayed the molecular ion peaks at appropriate $m/z = 390$ with the frequency of 18%, which was in agreement with the proposed structure. The ^1H NMR spectrum of **5a** showed two multiplets for four of the CH_2 groups ($\delta = 3.43\text{--}3.48, 4.75\text{--}4.88$ ppm), one singlet for the CH group (5.60 ppm) and aromatic region of the spectrum (7.12–7.98 ppm) for the aromatic moieties. The ^1H -decoupled ^{13}C NMR spectrum of **5a** showed 19 distinct resonances. Two signals at 180.0 and 180.9 ppm, which were assigned to two unsaturated 1,4-dicarbonyl groups, revealed the selective formation of **5a**.

Cytotoxic activity

At first, to compare the anti-cancer properties between heterocycles with a variety of structures, the cytotoxic activity of the synthesized compounds of our previous papers [20, 21], including pyrrolo[2,3-*d*]pyrimidines **9a–9c**, indenone-fused

Table 1 Synthesis of benzo[*g*]thiazolo[3,2-*a*]quinolines **5a–5l** (Scheme 1)

Entry	Ar	Product	Time/h ^a	Yield/%
1	$\text{C}_6\text{H}_5\text{--}$	5a	6	78
2	$4\text{-Cl-C}_6\text{H}_4\text{--}$	5b	2	91
3	$4\text{-F-C}_6\text{H}_4\text{--}$	5c	7	82
4	$4\text{-MeOCO-C}_6\text{H}_4\text{--}$	5d	3	80
5	$4\text{-HO-C}_6\text{H}_4\text{--}$	5e	3	90
6	$2\text{-HO-4-MeO-C}_6\text{H}_3\text{--}$	5f	6	72
7	$4\text{-Br-C}_6\text{H}_4\text{--}$	5g	3	80
8	$4\text{-O}_2\text{N-C}_6\text{H}_4\text{--}$	5h	1	95
9	$4\text{-MeO-C}_6\text{H}_4\text{--}$	5i	8	72
10	$3\text{-F-C}_6\text{H}_4\text{--}$	5j	6	68
11	$3\text{-Cl-C}_6\text{H}_4\text{--}$	5k	3	92
12	$3\text{-MeO-C}_6\text{H}_4\text{--}$	5l	8	69

^aThe reaction time of the second step

thiazolo[3,2-*a*]pyridines **10a–10c** and benzo[*g*]thiazolo[3,2-*a*]quinoline **5e** (Fig. 2), were evaluated against A549 cell, MCF-7 cell, and PC3 cell lines using the MTT colorimetric assay. The activity is expressed as 50% growth inhibitory concentration (IC_{50}) values at 48 h and the results are presented in Table 2. We used DMSO (1%) as a negative control and etoposide as a positive control. Among the different heterocyclic compounds in terms of chemical structure, compound **5e** ($\text{IC}_{50} = 2.5$ and $15 \mu\text{M}$) showed the highest cytotoxicity against every three cell line.

To further examine the effect of substitution on the anti-cancer properties of the benzo[*g*]thiazolo[3,2-*a*]quinolines, novel synthesized derivatives **5a–5l** were evaluated against A549 cells, MCF-7 cells, and PC3 cells. Compounds **5e**




Fig. 2 Chemical structure of different heterocycles

Table 2 In vitro cytotoxic activities of the different heterocycle compounds against A549 cells, MCF-7 cells, and PC3 cells lines

Compounds	Cell lines (IC ₅₀ /μM)		
	A549 cells	MCF-7 cells	PC3 cells
9a	> 100	> 100	> 100
9b	> 100	> 100	> 100
9c	> 100	> 100	> 100
10a	> 100	> 100	> 100
10b	> 100	> 100	> 100
10c	> 100	> 100	> 100
5e	15 ± 0.002	2.5 ± 0.005	2.5 ± 0.02
Etoposide	60 ± 0.01	30 ± 0.01	40 ± 0.06

Data represent mean ± SD of three independent experiments

(IC₅₀ = 2.5 μM) and **5 h** (IC₅₀ = 20 μM), which possessed 4-hydroxy and 4-nitro substituent moieties, respectively, displayed the highest cytotoxicity on the PC3 cell line (Table 3). In the synthesis of structurally drug-like compounds, compounds with numerous hydrogen bonding possibilities are superior to other compounds. These compounds are similar to normal metabolites and can easily be mistaken for metabolic activities by biological systems. Next, we treated cells with IC₅₀ of the **5e** compound for 24 h. Finally, using DAPI staining, we showed clear morphological changes and fragmentation in the chromatin within the nucleus of treated cells, but their morphology was not altered in untreated normal cells. Our results indicated that the **5e** compound induced cell death (Fig. 3).

Table 3 In vitro cytotoxic activities of the different derivatives against A549 cell, MCF-7 cell, and PC3 cell lines

Compounds	Cell lines (IC ₅₀ /μM)		
	A549 cells	MCF-7 cells	PC3 cells
5a	> 100	> 100	> 100
5b	> 100	> 100	> 100
5c	> 100	> 100	> 100
5d	> 100	> 100	> 100
5e	15 ± 0.002	2.5 ± 0.005	2.5 ± 0.02
5f	> 100	> 100	> 100
5g	> 100	> 100	> 100
5h	> 100	> 100	20 ± 0.12
5i	> 100	> 100	> 100
5j	> 100	> 100	> 100
5k	> 100	> 100	> 100
5l	> 100	> 100	> 100

Data represent mean ± SD of three independent experiments

It was previously shown that heterocyclic compounds containing nitrogen and sulfur heteroatoms have highly effective antitumor activities on cancer cells. Herein, we found that our synthesized benzo[*g*]thiazolo[3,2-*a*]quinolines derivatives exhibited the strongest inhibitory effect on cancer cells compared with other thiazole-based heterocycles [28].

Notably, our results demonstrated among the three cancer cell lines that we used, MCF-7 and PC3 cell lines were more sensitive than the A549 cell line to **5e**. Moreover, the

PC3 cell line was more sensitive to the other potent anti-cancer compound **5h**, compared to MCF-7 and A549 cell lines. Breast cancer and prostate cancer are the most common cancers in women and men in the world, respectively. Therefore, our findings can be helpful to design new therapeutic drugs against cancer. However, more studies will be required to show the molecular mechanisms involved in inducing cell death. Also, it is important to investigate the toxic side effects of new synthetic compounds by using in vivo experiments.

Conclusion


In this paper, we have developed a novel and efficient approach to the synthesis of heterocyclic scaffold comprising thiazole and quinoline, namely, 4-nitro-5-phenyl-1,2-dihydro-5*H*-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione through sequential Knoevenagel/Michael/intramolecular

N-cyclization sequences in EtOH media. Since sulfur- and nitrogen-containing compounds often show different biological activities and serve important functions in applications in the pharmaceutical industry, we evaluated derivatives' in vitro cytotoxic activity against tumor cells including A549 cells, MCF-7 cells, and PC3 cells using MTT assay. Finally, we showed cell death by evaluation of the nucleus of cells using DAPI staining. Depending on the above-mentioned results, it can be concluded that both compounds **5e** and **5h** have potent antitumor activity.

Experimental

1,1-Bis(methylthio)-2-nitroethene, cysteamine hydrochloride, 2-hydroxy-1,4-naphthoquinone, aromatic aldehydes, trimethylamine, and solvents were purchased from Aldrich and Merck Chemical Co. and used without further purification. IR spectra were measured with Bruker

Fig. 3 Inverted fluorescent microscopy images of chromatin damage occurrence in the nucleus of treated cells with **5e** compound (as sample) and DMSO (1%, as control), which had been stained with DAPI in different cancer cell lines. The experiments were performed three times (original microscope magnification, 40 \times , scale bar, 10 μ m)



Tensor 27 spectrometer. NMR spectra were recorded with a Bruker DRX-300 Avance instrument (300 MHz for ^1H and 75.4 MHz for ^{13}C) with CDCl_3 and $\text{DMSO-}d_6$ as solvents. Chemical shifts are given in ppm (δ) relative to internal TMS, and coupling constant (J) is reported in hertz (Hz). Mass spectra were recorded with an Agilent 5975C VL MSD with Triple-Axis detector operating at an ionization potential of 70 eV. Elemental analyses for C, H, and N were performed using a Heraeus CHNO-Rapid analyzer. Melting points were measured with an electrothermal 9100 apparatus.

Exemplary procedure

A mixture of 0.113 g cysteamine hydrochloride (1 mmol), 0.165 g 1,1-bis(methylthio)-2-nitroethylene (1 mmol), 139 mm³ triethylamine (1 mmol), and 10 cm³ EtOH in a 50 cm³ round-bottomed flask fitted with a reflux condenser was heated with stirring in an oil bath at reflux temperature for 4 h. After reaction completion (monitored by TLC, ethyl acetate/*n*-hexane, 6:4), 101 mm³ benzaldehyde (1 mmol) and 0.174 g 2-hydroxy-1,4-naphthoquinone (1 mmol) were added to the reaction mixture and it was stirred under 80 °C for a period of time shown in Table 1. Then, the reaction mixture was cooled to room temperature and filtered to give the crude product. The solid was washed with ethanol 96% and then dried in an oven at 150 °C to give product **5a** and analyzed by ^1H NMR and ^{13}C NMR. The crude product recrystallized from ethanol to afford the pure product (for CHN analyses).

4-Nitro-5-phenyl-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5a, C₂₁H₁₄N₂O₄S) Red powder; m.p.: 245–247 °C; yield 0.304 g (78%); IR (KBr): $\bar{\nu}$ = 3449, 2926, 1744 (C=O), 1664 (C=O), 1539 and 1347 (NO₂), 1445, 1243 (C–N), 1006 (C–O), 727 cm⁻¹; ^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ = 7.98–8.03 (t, J = 7.5 Hz, 1H), 7.85–7.90 (t, J = 7.5 Hz, 1H), 7.81 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 7.8 Hz, 2H), 7.26–7.30 (t, J = 7.2 Hz, 2H), 7.12–7.23 (m, 1H), 5.60 (s, 1H), 4.75–4.88 (t, J = 7.5 Hz, 2H), 3.43–3.48 (t, J = 7.5 Hz, 2H) ppm; ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$): δ = 181.9 (C=O), 180.0 (C=O), 158.9 (C=C–NO₂), 142.7 (C=C–N), 139.5, 134.9, 134.5, 132.1, 131.0, 128.9, 128.7, 127.8, 127.1, 125.7 (Ar), 124.7 (C=C–N), 123.0 (C–NO₂), 54.2 (CH₂N), 38.5 (CH₂S), 29.9 (CH) ppm; MS (EI, 70 eV): m/z (%) = 390 (18, M⁺), 344 (84), 313 (100), 267 (26), 234 (20), 183 (57), 139 (4), 77 (13).

5-(4-Chlorophenyl)-4-nitro-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5b, C₂₁H₁₃ClN₂O₄S) Red powder; m.p.: 272–274 °C; yield 0.386 g (91%); IR (KBr): $\bar{\nu}$ = 3447, 2926, 1742 (C=O), 1679 (C=O), 1585 and 1335 (NO₂), 1446, 1243 (C–N), 1006 (C–O), 727 cm⁻¹; ^1H NMR

(300 MHz, $\text{DMSO-}d_6$): δ = 7.98–8.06 (t, J = 7.59 Hz, 1H), 7.85–7.80 (t, J = 7.9 Hz, 1H), 7.82 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 8.7 Hz, 4H), 5.58 (s, 1H), 4.78–4.84 (t, J = 7.8 Hz, 2H), 3.42–3.48 (t, J = 7.8 Hz, 2H) ppm; ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$): δ = 181.9 (C=O), 179.9 (C=O), 159.1 (C=C–NO₂), 141.6 (C=C–N), 139.6, 134.9, 134.5, 132.4, 132.1, 131.0, 130.7, 128.8, 127.1, 125.7 (Ar), 124.1 (C=C–N), 122.7 (C–NO₂), 54.2 (CH₂N), 38.2 (CH₂S), 29.9 (CH) ppm; MS (EI, 70 eV): m/z (%) = 425.5 (7, [M + 1]⁺), 424.5 (20, M⁺), 378 (94), 313 (100), 267 (32), 234 (24), 210 (9), 172 (5), 111 (8), 75 (16).

5-(4-Fluorophenyl)-4-nitro-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5c, C₂₁H₁₃FN₂O₄S) Orange powder; m.p.: 214–215 °C; yield 0.334 g (82%); IR (KBr): $\bar{\nu}$ = 3416, 2925, 1735 (C=O), 1647 (C=O), 1547 and 1370 (NO₂), 1455, 1227 (C–N), 1016 (C–O), 718 cm⁻¹; ^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ = 7.98–8.02 (t, J = 7.5 Hz, 1H), 7.84–7.90 (t, J = 7.5 Hz, 1H), 7.81 (d, J = 6.9 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 7.08 (d, J = 8.1 Hz, 2H), 5.59 (s, 1H), 4.72–4.84 (t, J = 7.4 Hz, 2H), 3.40–3.47 (t, J = 7.4 Hz, 2H) ppm; ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$): δ = 181.9 (C=O), 180.0 (C=O), 162.0, 165.3 (Ar, d, $^1J_{CF}$ = 247.5 Hz), 159.0 (C=C–NO₂), 139.6 (C=C–N), 138.9, 134.9, 132.1 (Ar), 130.8, 130.7 (Ar, d, $^3J_{CF}$ = 9.0 Hz), 127.1, 125.7 (Ar), 124.4 (C=C–N), 123.0 (C–NO₂), 115.7, 115.4 (Ar, d, $^2J_{CF}$ = 21.7 Hz), 54.2 (CH₂N), 38.0 (CH₂S), 29.9 (CH) ppm; MS (EI, 70 eV): m/z (%) = 408 (20, M⁺), 362 (100), 313 (8), 267 (25), 234 (20), 207 (6), 170 (2), 139 (4), 75 (9).

Methyl 4-(4-nitro-6,11-dioxo-1,2,6,11-tetrahydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-5-yl)benzoate (5d, C₂₃H₁₆N₂O₆S) Red powder; m.p.: 289–290 °C; yield 0.358 g (80%); IR (KBr): $\bar{\nu}$ = 3424, 2941, 1762 (C=O), 1724 (C=O), 1677 (C=O), 1542 and 1334 (NO₂), 1441, 1245 (C–N), 1108 (C–O), 720 cm⁻¹; ^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ = 7.79–7.87, 7.99–8.02 (m, 6H), 7.49 (d, J = 8.1 Hz, 2H), 5.65 (s, 1H), 4.79–4.84 (t, J = 7.5 Hz, 2H), 3.80 (s, 3H), 3.44–3.50 (t, J = 7.5 Hz, 2H) ppm; ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$): δ = 181.8 (C=O), 179.9 (C=O), 166.3 (CO₂), 159.3 (C=C–NO₂), 147.7 (Ar), 139.6 (C=C–N), 134.9, 134.5, 132.1, 131.0, 129.7, 129.3, 129.0, 127.1, 125.7 (Ar), 124.0 (C=C–N), 122.5 (C–NO₂), 54.2 (CH₂N), 52.6 (OCH₃), 38.8 (CH₂S), 29.9 (CH) ppm.

5-(4-Hydroxyphenyl)-4-nitro-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5e, C₂₁H₁₄N₂O₅S) Red powder; m.p.: 310–311 °C; yield 0.365 g (90%); ^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ = 9.35 (s, 1H), 7.78–8.00 (m, 4H), 7.09 (d, J = 8.1 Hz, 2H), 6.62 (d, J = 8.1 Hz, 2H), 5.47 (s, 1H), 4.76–4.81 (t, J = 7.5 Hz, 2H), 3.41–3.46 (t, J = 7.5 Hz, 2H) ppm; ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$): δ = 181.9 (C=O), 180.0 (C=O), 158.4 (C=C–NO₂), 157.1 (Ar), 138.9 (C=C–N), 134.9, 134.4, 133.2, 132.0, 131.0, 129.8, 127.0, 125.7

(Ar), 125.1 (C=C–N), 123.4 (C–NO₂), 115.5 (Ar), 54.1 (CH₂N), 37.5 (CH₂S), 29.8 (CH) ppm.

5-(2-Hydroxy-4-methoxyphenyl)-4-nitro-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5f, C₂₂H₁₆N₂O₆S) Red powder; m.p.: 184–186 °C; yield 0.314 g (72%); ¹H NMR (300 MHz, DMSO-*d*₆): δ = 9.60 (s, 1H), 7.72–7.98 (m, 4H), 7.17 (d, *J* = 8.4 Hz, 1H), 6.31 (d, *J* = 8.4 Hz, 1H), 6.21 (s, 1H), 5.54 (s, 1H), 5.02–5.08 (t, *J* = 8.1 Hz, 2H), 4.43–4.52 (t, *J* = 8.1 Hz, 2H), 3.58 (s, 3H) ppm; ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 182.1 (C=O), 180.6 (C=O), 159.9 (C=C–NO₂), 158.8 (C–OMe), 157.7 (C–OH), 139.7 (C=C–N), 135.0, 134.3, 133.3, 131.8, 131.2, 126.9, 125.7, 123.7 (Ar), 122.0 (C=C–N), 120.0 (C–NO₂), 104.8 (Ar), 102.0 (Ar), 55.3 (OCH₃), 53.5 (CH₂N), 36.4 (CH₂S), 29.4 (CH) ppm.

5-(4-Bromophenyl)-4-nitro-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5g, C₂₁H₁₃BrN₂O₄S) Brown powder; m.p.: 286–288 °C; yield 0.375 g (80%); ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.97–8.03 (t, *J* = 7.4 Hz, 1H), 7.84–7.90 (t, *J* = 7.1 Hz, 1H), 7.82 (d, *J* = 6.9 Hz, 2H), 7.44 (d, *J* = 7.9 Hz, 2H), 7.29 (d, *J* = 8.6 Hz, 2H), 5.57 (s, 1H), 4.75–4.83 (t, *J* = 8.1 Hz, 2H), 3.40–3.48 (t, *J* = 8.1 Hz, 2H) ppm; ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 181.4 (C=O), 179.1 (C=O), 159.2 (C=C–NO₂), 142.9 (C=C–N), 139.5, 134.9, 134.5, 132.3, 131.7, 131.0, 127.1, 125.7, 124.4, 124.1 (Ar), 122.7 (C=C–N), 120.9 (C–NO₂), 54.2 (CH₂N), 38.3 (CH₂S), 29.9 (CH) ppm; MS (EI, 70 eV): *m/z* (%) = 470 (11, [M + 1]⁺), 469 (4, M⁺), 424 (60), 313 (100), 267 (21), 234 (17), 210 (6), 157 (3), 113 (2), 76 (9).

4-Nitro-5-(4-nitrophenyl)-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5h, C₂₁H₁₃N₃O₆S) Red powder; m.p.: 228 °C; yield 0.413 g (95%); ¹H NMR (300 MHz, DMSO-*d*₆): δ = 8.12 (d, *J* = 7.6 Hz, 2H), 7.99–8.07 (t, *J* = 6.8 Hz, 1H), 7.78–7.92 (m, 3H), 7.64 (d, *J* = 7.6 Hz, 2H), 5.73 (s, 1H), 4.79–4.88 (t, *J* = 7.9 Hz, 2H), 3.44–3.51 (t, *J* = 7.9 Hz, 2H) ppm; ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 181.8 (C=O), 179.9 (C=O), 159.0 (C=C–NO₂), 149.7 (Ar), 147.1 (Ar), 139.9 (C=C–N), 135.0, 134.5, 132.0, 130.9, 130.3, 127.1, 125.8, 124.0 (Ar), 123.5 (C=C–N), 122.3 (C–NO₂), 53.5 (CH₂N), 39.1 (CH₂S), 29.9 (CH) ppm; MS (EI, 70 eV): *m/z* (%) = 435 (19, M⁺), 389 (62), 343 (9), 313 (100), 267 (20), 234 (15), 210 (5), 178 (2), 139 (3), 76 (7).

5-(4-Methoxyphenyl)-4-nitro-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5i, C₂₂H₁₆N₂O₅S) Red powder; m.p.: 208–210 °C; yield 0.302 g (72%); ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.79–7.99 (m, 4H), 7.23 (d,

J = 8.7 Hz, 2H), 6.79 (d, *J* = 8.7 Hz, 2H), 5.53 (s, 1H), 4.78–4.86 (t, *J* = 7.5 Hz, 2H), 3.65 (s, 3H), 3.42–3.47 (t, *J* = 7.5 Hz, 2H) ppm; ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 181.5 (C=O), 179.9 (C=O), 158.9 (C=C–NO₂), 157.9 (C–OCH₃), 141.5 (C=C–N), 139.2, 133.6, 134.1, 131.7, 128.4, 128.0, 127.3, 125.5 (Ar), 123.5 (C=C–N), 122.8 (C–NO₂), 114.2 (Ar), 55.5 (OCH₃), 54.2 (CH₂N), 39.1 (CH₂S), 29.9 (CH) ppm.

5-(3-Fluorophenyl)-4-nitro-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5j, C₂₁H₁₃FN₂O₄S) Orange powder; m.p.: 273–275 °C; yield 0.277 g (68%); IR (KBr): $\bar{\nu}$ = 3447, 2927, 1741 (C=O), 1685 (C=O), 1539 and 1305 (NO₂), 1448, 1210 (C–N), 1115 (C–O), 776 cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.80–8.02 (m, 4H), 7.00–7.34 (m, 4H), 5.60 (s, 1H), 4.79–4.84 (t, *J* = 7.5 Hz, 2H), 3.43–3.48 (t, *J* = 7.5 Hz, 2H) ppm; ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 181.9 (C=O), 179.9 (C=O), 164.2, 161.0 (Ar, d, ¹*J*_{CF} = 240 Hz), 159.2 (C=C–NO₂), 145.2 (C=C–N), 139.7, 134.9, 134.5, 132.1, 131.0 (Ar), 130.7, 130.6 (Ar, d, ³*J*_{CF} = 8.3 Hz), 127.1, 125.8, 125.0 (Ar), 124.0 (C=C–N), 122.6 (C–NO₂), 115.7, 115.4 (d, ²*J*_{CF} = 21.7 Hz, Ar), 114.5, 114.8 (d, ²*J*_{CF} = 21.0 Hz, Ar), 54.2 (CH₂N), 38.5 (CH₂S), 29.9 (CH) ppm.

5-(3-Chlorophenyl)-4-nitro-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5k, C₂₁H₁₃ClN₂O₄S) Red powder; m.p.: 285 °C; yield 0.390 g (92%); ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.98–8.04 (t, *J* = 8.2 Hz, 1H), 7.84–7.92 (t, *J* = 8.2 Hz, 1H), 7.82 (d, *J* = 6.9 Hz, 2H), 7.38 (s, 1H), 7.29–7.31 (m, 3H), 5.57 (s, 1H), 4.77–4.85 (t, *J* = 7.9 Hz, 2H), 3.42–3.48 (t, *J* = 7.9 Hz, 2H) ppm; ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 181.9 (C=O), 179.9 (C=O), 159.2 (C=C–NO₂), 144.8 (Ar), 139.7 (C=C–N), 134.9, 134.5, 133.4, 132.1, 130.9, 130.7, 128.7, 127.8, 127.6, 127.0, 125.7 (Ar), 123.9 (C=C–N), 122.6 (C–NO₂), 54.2 (CH₂N), 38.7 (CH₂S), 29.9 (CH) ppm.

5-(3-methoxyphenyl)-4-nitro-1,2-dihydro-5H-benzo[*g*]thiazolo[3,2-*a*]quinoline-6,11-dione (5l, C₂₂H₁₆N₂O₅S) Red powder; m.p.: 245–247 °C; yield 0.290 g (69%); IR (KBr): $\bar{\nu}$ = 3448, 2925, 1743 (C=O), 1665 (C=O), 1536 and 1341 (NO₂), 1440, 1199 (C–N), 1046 (C–O), 718 cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆): δ = 7.79–8.01 (m, 4H), 7.14–7.20 (t, *J* = 8.1 Hz, 1H), 6.87 (d, *J* = 7.8 Hz, 1H), 6.82 (s, 1H), 6.76 (d, *J* = 8.1 Hz, 1H), 5.57 (s, 1H), 4.74–4.84 (t, *J* = 7.5 Hz, 2H), 3.68 (s, 3H), 3.42–3.47 (t, *J* = 7.5 Hz, 2H) ppm; ¹³C NMR (75 MHz, DMSO-*d*₆): δ = 181.9 (C=O), 180.0 (C=O), 159.7 (C=C–NO₂), 158.8, 144.0 (Ar), 139.5 (C=C–N), 134.9, 134.4, 132.1, 131.1, 130.0, 127.0, 125.8, 124.6 (Ar), 122.9 (C=C–N), 120.9 (C–NO₂), 115.0, 112.5 (Ar), 55.4 (OCH₃), 54.2 (CH₂N), 38.4 (CH₂S), 29.9 (CH) ppm.

Cell lines and cell culture

Human non-small cell lung cancer A549 cells, human breast cancer MCF-7 cells, and prostate cancer PC3 cells were received from Pasture Institute, Tehran, Iran. MCF-7 cells were grown in RPMI 1640 medium, A549 cells and PC3 cells were grown in DMEM medium. All media contain 10% fetal bovine serum (FBS), penicillin G, streptomycin 100 µg/cm³ and 1% L-glutamine. The cells were cultured and incubated under humidified 5% CO₂ atmosphere at 37 °C.

MTT assay

The effect of compound treatment on the viability of cancer cell lines was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or MTT) assay (MTT assay kit, Bio IDEA, CatNo:BI1017, Iran) based on the ability of live cells to cleave the tetrazolium ring to a molecule that absorbs at 4900 nm as per the manufacturer's instructions [29]. Etoposide (was kindly provided by Dr. A. Foroumadi, Tehran Medical Science University, Iran) and dimethyl sulfoxide (DMSO) were used as the positive and negative controls, respectively [30]. Briefly, cells were plated in 96-well culture plates (5 × 10³ cells/well). After 24 h incubation, the cells were treated with different concentrations of the compounds. After 48 h at 37 °C, the medium was removed and 100 µm³ of MTT reagent (1 mg/cm³) was added to each well, and cells were further incubated at 37 °C for 4 h. The MTT solution was removed, 50 µm³ of DMSO was added to each well to dissolve formazan crystals, and the plates were gently shaken for 10 min, followed by reading with an ELISA plate reader (Biotek ELx 800, USA). The 50% inhibition concentration (IC₅₀) was defined as the concentration that inhibited cell proliferation by 50% when compared to DMSO-treated cells (as negative control).

DAPI staining assay

DAPI staining assay was used to determine chromatin changes. MCF-7 cells, PC3 cells, and A549 cells were seeded in six well plates (5 × 10⁴ cells/well) containing 12 mm coverslips and subsequently treated for **5e** compound (sample or treated cells) and DMSO (control or untreated cells) for 24 h. Cells were then fixed with 3.7% paraformaldehyde, permeabilized in 0.5% (w/v) Triton X-100, and 1% BSA (w/v) for 5 min, washed in PBS, and stained with DAPI (Sigma-Aldrich, USA). All images were taken by an inverted fluorescent microscope (Nikon Eclipse Ti-E).

Acknowledgements We are grateful to the University of Guilan and Imam Khomeini International University, Iran, for financial support.

References

- Rakitin OA (2009) *Arkivoc* i:129
- Feng M, Tang B, Liang H, Jiang S (2016) *Curr Top Med Chem* 16:1200
- Park H, Hwang KY, Oh KH, Kim YH, Lee JY, Kim K (2008) *Bioorg Med Chem* 16:284
- El-Hag Ali GAM, Khalil AK, Lamphon RQ, El-Maghraby AA (2005) *Phosphorus. Sulfur Silicon Relat Elem* 180:1909
- Boominathan M, Nagaraj M, Maheshwaran C, Muthusubramanian S, Bhuvanesh N (2014) *J Heterocycl Chem* 51:244
- El-Gaby MSA, Al-Sehemi AG, Mohamed YA, Ammar YA (2006) *Phosphorus. Sulfur Silicon Relat Elem* 181:631
- Shi F, Li C, Xia M, Miao K, Zhao Y, Tu S, Zheng W, Zhang G, Ning M (2009) *Bioorg Med Chem Lett* 19:5565
- Acheson RM, Elmore NF (1978) *Adv Heterocycl Chem* 23:263
- Khalifa NM, Adel AH, Abd-Elmoez SI, Fathalla OA, El-Gwaad AAA (2015) *Res Chem Intermed* 41:2295
- Aberg V, Sellstedt M, Hedenström M, Pinkner JS, Hultgren SJ, Almqvist F (2006) *Bioorg Med Chem* 14:7563
- Park H, Hwang KY, Oh KH, Kim YH, Lee JY, Kim K (2008) *Bioorg Med Chem* 16:284
- Ali GH, Khalil A, Ahmed AHA, El-Gaby MSA (2002) *Acta Chim Slov* 49:365
- Voskiene A, Sapjianskaite B, Mickevicius V, Jonuskiene I, Stasevych M, Komarovska-Porokhnyavets O, Musyanovych R, Novikov V (2012) *Molecules* 17:14434
- Ferreira SB, da Silva FD, Bezerra FAFM, Lourenco MCS, Kaiser CR, Pinto AC, Ferreira VF (2010) *Arch Pharmazie* 343:81
- Siegel RL, Miller KD, Jemal A (2017) *CA Cancer J Clin* 67:7
- Perrino MP, del Villar-Guerra R, Sañudo MC, Calvo LA, González-Ortega A (2010) *Tetrahedron* 66:2815
- Chen HL, Guo HY (2012) *J Chem Res* 36:162
- Yildirim M, Celikel D, Evis N, Knight DW, Kariuki BM (2014) *Tetrahedron* 70:5674
- Dotsenko VV, Bushmarinov IS, Goloveshkin AS, Chigorina EA, Frolov KA, Krivokolysko SG (2017) *Phosphorus, Sulfur Silicon Relat Elem* 192
- Bayat M, Nasri S, Notash B (2017) *Tetrahedron* 73:1522
- Bayat M, Nasri S (2018) *J Mol Struct* 1154:366
- Nasri S, Hosseini FS, Bayat M (2018) *Tetrahedron* 74:4409
- Bayat M, Hosseini F, Notash B (2016) *Tetrahedron Lett* 57:5439
- Noyori R (2005) *Chem Commun* 14:1807
- Talaviya S, Majmudar F (2012) *J Med Sci* 1:7
- Fan Y, Liu S, Chen N, Shao X, Xu X, Li Z (2015) *Synlett* 26:393
- Yildirim M, Celikel D, Dürüst Y, Knight DW, Kariuki BM (2014) *Tetrahedron* 70:2122
- Martins P, Jesus J, Santos S, Raposo L, Roma-Rodrigues C, Baptista P, Fernandes A (2015) *Molecules* 20:16852
- Denizot F, Lang R (1986) *J Immunol Methods* 89:271
- Mahdavi M, Dianat S, Khavari B, Moghimi S, Abdollahi M, Safavi M, Mouradzadegun A, Kabudanian Ardestani S, Sabourian R, Emami S, Akbarzadeh T, Shafiee A, Foroumadi A (2017) *Chem Biol Drug Des* 89:797